Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

32.94
BRL
-0.42
(-1.26%)
-3.23EPS
48.90BMarket Cap
Feb 10Next Earn

Total Valuation

BRL

As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh carries a market capitalization of 48.90B, placing it among publicly traded companies globally. Its enterprise value stands at 47.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap48.90B
Enterprise Value47.90B

Important Dates

Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's next confirmed earnings release is scheduled for February 10, 2027.

Earnings Date2/10/2027

Share Statistics

As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has 1.15B shares outstanding.

Shares Outstanding1.15B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 20.80, and the price-to-book ratio stands at 187.53.

PS Ratio20.80
PB Ratio187.53
P/TBV Ratio208.96
P/FCF Ratio-33.25
P/OCF Ratio-34.49

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 20.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 47.90B versus a market cap of 48.90B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales20.50

Financial Position

As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh maintains a current ratio of 4.14, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,980.43, indicating moderate leverage, while an interest coverage ratio of -7.26 demonstrates limited ability to service its debt obligations.

Current Ratio4.14
Quick Ratio3.86
Debt / Equity1,980.43
Debt / EBITDA-1.47
Interest Coverage-7.26

Financial Efficiency

BRL

Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh posted a negative return on equity (ROE) of -280.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.37, reflecting losses generated across the asset base. The company generates approximately 2.93M in revenue per employee across its workforce of 798.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-280.50
Return on Assets (ROA)-46.37
Revenue Per Employee2.93M
Employee Count798.00

Taxes

BRL

Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh recorded an income tax benefit of -35.14M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.75B and -3.75B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-35.14M

Stock Price Statistics

BRL

As of the close on November 16, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's stock has gained approximately 22.73% over the past 52 weeks. The 50-day moving average sits at 45.52, while the 200-day moving average is 45.66.

52-Week Price Change22.73%
50-Day Moving Average45.52
200-Day Moving Average45.66

Income Statement

BRL

Over the twelve months ended September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh generated 2.34B in revenue and converted that into -3.75B in net income, yielding earnings per share of -3.23. EBITDA reached -3.53B, while operating income came in at -3.66B.

Revenue2.34B
Operating Income-3.66B
Pretax Income-3.75B
Net Income-3.75B
EBITDA-3.53B
EBIT-3.66B
Earnings Per Share (EPS)-3.23

Balance Sheet

BRL

As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh holds 6.18B in cash and equivalents against 5.18B in total debt, resulting in a net debt position of 4.23B. Total book value stands at 260.75M, with working capital of 5.07B providing operational flexibility.

Cash & Cash Equivalents6.18B
Total Debt5.18B
Net Debt4.23B
Equity (Book Value)260.75M
Book Value Per Share0.23
Working Capital5.07B

Cash Flow

BRL

Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh produced -1.41B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -62.16M in capital expenditures, free cash flow totaled -1.47B - equivalent to -1.29 per share.

Operating Cash Flow-1.41B
Capital Expenditures-62.16M
Free Cash Flow-1.47B
FCF Per Share-1.29

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -156.86 and net profit margin of -160.64 provide insight into operational efficiency.

Operating Margin-156.86
Pretax Margin-160.58
Profit Margin-160.64
EBITDA Margin-150.96

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -3.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.23, meaning Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-8.23
FCF Yield-3.01

Scores

As of September 30, 2026, Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has an Altman Z-Score of 1.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.05